PharmaNutra S.p.A. a company specialised in mineral and iron-based nutritional supplements and medical devices for muscles and joints, is ready to face the great challenge of the FIA World

Roche today announced that it has expanded its collaboration with Janssen Biotech Inc. to create companion diagnostics for targeted therapies, further strengthening research and innovation activities.

Astellas Pharma Inc. today announced its commitment to achieve net zero greenhouse gas emissions by 2050.Astellas Pharma Inc. today announced its commitment to achieve net zero greenhouse gas emissions by 2050.

Envision Pharma Group a leading global technology-enabled commercialization, integrated medical capabilities and solutions, and data analytics partner to the life sciences industry, announced

Kenya Medical Research Institute NEC Corporation and Nagasaki University have developed an immunization management system based on digital biometrics for newborns in Kenya. Validation

Ellipses Pharma, a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for EP0042

Seqens Group, an integrated leader in the development and manufacture of active pharmaceutical ingredients (APIs) and intermediates, today announced that it has opened Seqens Boston R&D Center, a state-of-the-art, 15,000 square-foot R&D center in Devens, Mass. Serving as one of the company’s global centers

Ajinomoto Co., Inc.today announced a license agreement with Exelixis, Inc. to develop AJICAP , its proprietary site-specific bioconjugation and Linker Technology of Ajinomoto Co., in the development of certain Exelixis Antibody-Drug Conjugate programs.Exelixis is a commercially successful Exelixis is a commercially successful

Hemab Therapeutics, a clinical-stage biotechnology company developing next-generation therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the first patient has been dosed in a Phase 1/2 study evaluating HMB-001 for the treatment of the severe bleeding disorder Glanzmann